Satellos Bioscience Inc.

Recent News

  • Satellos Bioscience Announces In-Licensing of New Patent Application

    Toronto, Ontario--(Newsfile Corp. - June 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has licensed a provisional patent application, recently filed with the United States Patent and Trademark Office and titled "MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION," from the Ottawa Hospital Research Institute ("OHRI"). "This patent filing broadens our intellectual property portfolio...

    2022-06-29 6:20 PM EDT
  • Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society

    Toronto, Ontario--(Newsfile Corp. - June 22, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been admitted as a Fellow of the Royal Society, the UK's national science academy and a Fellowship of the world's most revered scientists. With admission to the Royal Society, founded in 1660...

    2022-06-22 7:00 AM EDT
  • Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant

    Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been named one of only three 2022 recipients of a prestigious grant awarded from Defeat Duchenne Canada, the country's only national charity dedicated to ending Duchenne muscular dystrophy ("Duchenne"). "We're very excited for Michael...

    2022-06-17 7:00 AM EDT
  • Satellos Bioscience Inc. to Present at Bio International Convention 2022

    Dr. Ryan Mitchell, PhD and Director of Business Development to highlight Satellos’ novel muscle regeneration technology on June 15Toronto, Ontario--(Newsfile Corp. - June 14, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Director of Business Development, Ryan Mitchell, PhD will be presenting at the upcoming BIO International Convention 2022 in San Diego on June...

    2022-06-14 7:50 AM EDT
  • Satellos Bioscience Inc. Announces First Quarter Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutic drugs that change the way degenerative muscle diseases are treated, today announced its unaudited financial results and operational highlights for the quarter ended March 31, 2022 ("Q1 2022"). All dollar amounts in this press release are in Canadian dollars unless otherwise noted."The early months of 2022 has been a productive period for Satellos as we...

    2022-05-31 7:00 AM EDT
  • Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - April 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ending December 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted."2021 was a transformative year for Satellos, as we continue to advance game changing science that can have an immense impact...

    2022-04-29 7:30 PM EDT
  • Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

    Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos Bioscience was invited to present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. The conference brings together U.S., Canadian, and international investors interested in the latest developments in the Canadian healthcare sector.Event: 2022 Bloom Burton & Co. Healthcare...

    2022-04-26 7:00 AM EDT
  • Satellos Bioscience Inc. to Present Game Changing Science at Upcoming European Molecular Biology Organization Workshop

    Toronto, Ontario--(Newsfile Corp. - April 21, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Ryan Mitchell, PhD and Director of Business Development will be presenting a poster on Satellos' game changing science during an upcoming European Molecular Biology Organization (EMBO) workshop on muscle formation, maintenance, regeneration and pathology. The workshop will take place in Gouvieux,...

    2022-04-21 7:00 AM EDT